Previous 10 | Next 10 |
Fiscal Year 2022 Fourth Quarter Highlights Net sales of $87.0 million increased 13.2% compared to the prior-year quarter Gross margin of 53.4% declined 170 basis points year over year GAAP loss per share of $0.16 and adjusted earnings per share of $0.01 ...
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentat...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that it will report f...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, Pre...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, Pre...
The market already has plenty to worry about between looming interest rate hikes, decades-high inflation, and geopolitical tensions. But it now has another concern: Mounting COVID cases and restrictions in China could have a profound impact on the global economic outlook in the near future....
AngioDynamics came in a little short on revenue and supply chain costs are still a significant headwind, but the company's growth-oriented businesses seem to be outperforming. Auryon and AngioVac/AlphaVac are increasingly important to the long-term story, with both performing well in ...
Shares of AngioDynamics (NASDAQ: ANGO) stock, the maker of "NanoKnife" surgical tools for zapping cancer cells with electricity , surged in Thursday morning trading -- up 10.1% as of 11:55 a.m. ET -- after beating analyst earnings targets. Heading into fiscal Q3 2022, analys...
AngioDynamics, Inc. (ANGO) Q3 2022 Results Conference Call April 07, 2022 08:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Steve Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James Bi...
The shares AngioDynamics (NASDAQ:ANGO) are trading sharply higher in the morning hours Thursday after the medical device maker reported better than expected earnings for 3Q FY22 and kept its guidance for the full year unchanged in line with the consensus. However, the top line missed the...
News, Short Squeeze, Breakout and More Instantly...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that its management is schedule...
Equity Bancshares Inc. Class A (EQBK) is expected to report $0.92 for Q2 2024 Bank of America Corporation (BAC) is expected to report $0.79 for Q2 2024 Aehr Test Systems (AEHR) is expected to report $0.09 for Q4 2024 America Movil S.A.B. de C.V.n Depositary Shares (each representing t...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourt...